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CASE STUDY OF A PATIENT WITH HIV-AIDS AND VISCERAL LEISHMANIASIS  
CO-INFECTION IN MULTIPLE EPISODES
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SUMMARY
Report of a 45-year-old male farmer, a resident in the forest zone of Pernambuco, who was diagnosed with human immunodeficiency 
virus (HIV) in 1999 and treated using antiretroviral (ARV) drugs. In 2005, the first episode of visceral leishmaniasis (VL), as assessed 
by parasitological diagnosis of bone marrow aspirate, was recorded. When admitted to the hospital, the patient presented fever, 
hepatosplenomegaly, weight loss, and diarrhea. Since then, six additional episodes of VL occurred, with a frequency rate of one per 
year (2005-2012, except in 2008). In 2011, the patient presented a disseminated skin lesion caused by the amastigotes of Leishmania, 
as identified by histopathological assessment of skin biopsy samples. In 2005, he was treated with N-methyl-glucamine-antimony and 
amphotericin B deoxycholate. However, since 2006 because of a reported toxicity, the drug of choice was liposomal amphotericin B. 
As recommended by the Ministry of Health, this report emphasizes the need for HIV patients living in VL endemic areas to include 
this parasitosis in their follow-up protocol, particularly after the first infection of VL.
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INTRODUCTION
Cases of visceral leishmaniasis (VL) co-infection with human 
immunodeficiency virus (HIV) and acquired immune deficiency 
syndrome AIDS (VL/HIV-AIDS) have been registered in 35 countries, 
mainly in southwestern Europe. VL/HIV-AIDS co-infections increase 
in areas where these two diseases coexist, as observed in Asian, African, 
and Latin American countries. In the latter group, Brazil has the highest 
number of cases¹.
In 2011, in Brazil, VL appeared in 22 of the 27 Brazilian states, 
covering urban and suburban areas. Between 1998 and 2009, the annual 
average was 3,349 cases7. From 1980 to 2011 in Brazil, 608,230 cases of 
AIDS were reported. This epidemic tends to spread to poorly inhabited 
macro-regions as well as to medium and small cities8. When AIDS and 
VL databases were correlated, 176 cases of VL/HIV-AIDS co-infection 
were detected among the Federal States7.
Several episodes of VL are frequent in cases of VL/HIV-AIDS 
co-infection. According to BOURGEOIS et al., 2010, these patients 
present a novel nosological entity called ‘active chronic visceral 
leishmaniasis’. This condition may be termed ‘chronic’ because of the 
presence of relapses over a period of several years and ‘active’ because 
of the continuous blood circulation of the parasite. On the other hand, 
it’s impossible to know if repeated episodes are relapses or reinfections 
by using conventional parasitological and immunological methods15. 
Some studies show that individuals with HIV/AIDS and infected with 
VL often present atypical clinical manifestations and high incidence of 
relapse5,22,24,25. Molecular methods confirm that more than 90% of these 
cases are relapses, rather than reinfections27. The discrimination between 
relapses and reinfection can be made by molecular techniques based on 
restriction fragment length polymorphism (RFLP) analysis. The use 
of this technology may provide the physician with more information 
to determine Leishmania infections in patients who do not respond to 
treatment20.
Professionals, who treat patients with HIV/AIDS, report that this 
co-infection was not prioritized because of the variety of diseases related 
to immunosuppression, in addition to not being included among the 
AIDS-defining conditions11. To alert healthcare professionals about this 
association, we describe the case of a patient presenting multiple VL/HIV-
AIDS co-infections during the seven years of evolution of this disease.
CASE REPORT
In 1999, a 31-year-old male farmer, who was a resident in the forest 
zone of Pernambuco, was admitted to the Clinics Hospital of the Federal 
University of Pernambuco. At the time of admission, he presented with 
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asthenia and headache, and had diarrhea for at least 30 days. He was 
diagnosed with HIV, and began receiving antiretroviral therapy (ART) 
with stavudine, lamivudine, and efavirenz. Meanwhile, his 25-year-old 
partner and 9-month-old daughter were diagnosed with HIV infection.
Five years after initiating ART, the patient presented virological 
failure; after genotyping, his treatment was changed to tenofovir, 
lamivudine, and lopinavir/ritonavir. In 2005, he was diagnosed with VL 
as assessed by directly testing Leishmania in the bone marrow aspirate 
and initially treated with N-methyl-glucamine-antimony. However, 
because of pancreatitis, the patient began receiving amphotericin B, 
which was then replaced by a liposomal formulation because of the 
onset of renal failure.
In 2011, the patient presented disseminated cutaneous lesions caused 
by Leishmania, as assessed by histopathological analysis of skin biopsy 
samples. In July 2012, the patient was readmitted for presenting febrile 
disease with splenomegaly and pancytopenia, in addition to showing 
positive results for laboratory tests for leishmaniasis (Table 1). After 
administration of liposomal amphotericin B deoxycholate, the patient’s 
condition improved, and he was discharged upon recommendation of 
a secondary prophylaxis by administering liposomal amphotericin B 
twice a week. Between 2005 and 2012, seven VL infections occurred, 
as shown in the Table 1.
DISCUSSION
This case describes some of the many clinical, diagnostic, and 
epidemiologic aspects of VL/HIV-AIDS co-infection. Immunosuppression 
caused by HIV might lead to the development of symptomatic VL14. In 
turn, VL might promote the clinical progression of HIV and of AIDS-
defining conditions, thus, reducing the possibility of recovery after 
treatment and increasing the incidence of relapse11. This report showed 
that individuals with HIV/AIDS and living in endemic areas of VL 
should include VL assessment in their follow-up protocol. After the first 
co-infection, by means of clinical and laboratory support, a follow-up 
Table 1 
Description of clinical events, additional diagnostics, and treatment for the case of co-infection from Pernambuco, between 1999 and 2012
Period 
(month/year) Clinical events
CD4+ T cells 
(cells/mm3)
Viral load 
(copies/mL) Laboratory diagnosis Treatment
Prophylactic 
treatment
09/99 Positive for HIV N.A. N.A. N.A. d4T + 3TC + EFV N.A.
05/04 24 208,000 N.A. TDF + 3TC + LPVr N.A.
03/05 154 29,000 N.A. TDF + 3TC + LPVr N.A.
06/05
Visceral leishmaniasis 
(Hepatosplenomegaly/
diarrhea/fever/ cachexia/
pancytopenia)
N.A. N.A. B.M. aspirate
TDF + 3TC + LPVr 
N-methyl-glucamine-
antimonya, amphotericin Bb, 
liposomal amphotericin
N.A.
11/05 58 87,800 N.A. TDF + 3TC + LPVr N.A.
02/06 Visceral leishmaniasis (Second infection) 170 <50 B.M. aspirate
TDF + 3TC + LPVr 
liposomal amphotericin
N-methyl-
glucamine-
antimony
02/07 Visceral leishmaniasis (Third infection) 72 N.A. B.M. aspirate
TDF + 3TC + LPVr 
liposomal amphotericin N.D
06/08 113 <50 N.A. TDF + 3TC + LPVr Amphotericin B
07/09 Visceral leishmaniasis (Fourth infection) 141 <50 B.M. aspirate
TDF + 3TC + LPVr 
liposomal amphotericin
Amphotericin 
B
05/10 Visceral leishmaniasis (Fifth infection) 83 <50 B.M. aspirate
TDF + 3TC + LPVr 
liposomal amphotericin
Amphotericin 
B
05/11
Skin lesions on the forehead/
right forearm; Visceral 
leishmaniasis (Sixth 
infection)
120 <50
Skin biopsy, rK39 
rapid test, DAT, latex 
agglutination test, and 
PCR
TDF + 3TC + LPVr 
liposomal amphotericin
Liposomal 
amphotericin
07/12
Visceral leishmaniasis 
(Seventh infection)
(Splenomegaly/diarrhea/
fever/cachexia/pancytopenia)
114 <50
rK39 rapid test , DAT, 
latex agglutination test, 
and PCR
TDF + 3TC + LPVr 
amphotericin Bb, liposomal 
amphotericin
Liposomal 
amphotericin
HIV, human immunodeficiency virus; N.A., not available; N.D., not done; B.M. aspirate, bone marrow aspirate; d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; 
TDF, tenofovir; LPVr, lopinavir/ritonavir; DAT, direct agglutination test; PCR, polymerase chain reaction. aDeveloped acute pancreatitis. bDeveloped renal failure.
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protocol of the patient should be created for early detection of relapse 
and re-infection.
One of the common features of co-infection is the increased tendency 
of relapse, observed in 37-80% of the patients22. Additionally, in some 
cases a chronic course with multiple occurrences might take place. This 
can be attributed not only to immunodeficiency but also to re-infection, 
host deficiencies correlating with ART, secondary prophylaxis, and 
CD4+ lymphocyte count16,18. CD4+ lymphocyte count is one of the 
most significant prognostic factors for survival11,22. VL usually appears 
as an opportunistic disease in HIV patients when CD4+ cell count is less 
than 200 cells/mm3 (1,6,12,13,17,25). During the seven years of follow-up, the 
patient presented a CD4+ cell count ≤ 170 cells/mm3. This represents 
an important predictor of relapse. Relapses of VL are suggested to occur 
mainly in individuals with poor responses to antiretroviral treatment who 
have no improvement in CD4+ counts with a few exceptions3,9.
Based on clinical and biological [polymerase chain reaction (PCR)-
based] follow-up, an ‘active chronic visceral leishmaniasis’5 has been 
proposed by BOURGEOIS et al. (2010). In our case, only the 6th and 7th 
episodes were able to have the peripheral blood (PB) analyzed by PCR, 
which showed positive results for Leishmania spp. As PCR-RFLP was 
only found in the 7th sample episode, the etiological agent is Leishmania 
chagasi, according to the pattern of bands defined by SCHONIAN et 
al. (2003)26. Due to the absence of PB samples in previous episodes, the 
analysis by PCR-RFLP was not made. Therefore, it wasn’t possible to 
distinguish between relapse and reinfection or characterize the case as 
‘chronic visceral leishmaniasis’. Despite the medical importance of a 
clinical and laboratory monitoring of coinfected patients, this practice 
is still little used12,19,20.
ART plays an important role in reducing the effect of opportunistic 
diseases and in recent studies has shown a reduction in the incidence 
of VL. Studies in individuals with HIV/AIDS treated using ARV drugs 
showed a similar incidence of VL relapse when compared to studies of the 
pre-highly active antiretroviral therapy (HAART) era11,14. The increased 
survival resulting from ART might partially explain the high incidence 
of relapse observed in this population18. In the present study, during the 
eight years of follow-up, we observed seven VL infections, despite the 
patient receiving ART before the first infection.
VL manifestations associated with HIV infection might appear in a 
classical form, particularly in patients from VL-endemic areas, as well 
as with relatively aggressive symptoms that are sometimes non-specific 
and difficult to clinically diagnose11. In individuals with HIV/AIDS 
and presenting symptoms such as asthenia, anorexia, and weight loss, 
VL might be responsible for 7-23% of instances of fever of unknown 
origin11. This patient presented classic clinical manifestations during 
the study period, although in 2011, we observed the formation of skin 
lesions because of the parasite, as assessed by histopathological analysis.
Among the previously treated VL cases, several patients present a 
skin condition characterized by macular, popular, or nodular lesions, 
called Post-kala-azar dermal Leishmaniasis (PKDL) caused by the 
amastigotes of Leishmania donovani on the Indian subcontinent (India, 
Nepal, Bangladesh) and east Africa (Sudan, Ethiopia, Kenya) and caused 
by Leishmania chagasi in South America where it is rarely reported, 
as well as its presence in HIV positives2,4,23,28. It is worth noticing that 
exclusive involvement of the skin is an unusual condition, because 
the simultaneous appearance of skin lesions along with other VL 
manifestations was more frequently observed21. In this case, the skin 
lesion suggests a clinical PKDL, which developed five years after the 
first VL episodes, administration of multiple therapeutic regimens, and 
treatments of discontinuous secondary prophylaxis. Although it has been 
viewed amastigotes in biopsy specimens obtained from skin lesions, 
the hypothesis of PKDL can be suggested but not stated categorically 
because there was no characterization of Leishmania species involved 
in the cutaneous lesions, and may have been an infection of some sort 
cutaneous Leshmania endemic to the region as L. braziliensis.
Several studies on co-infected individuals show that they present a 
decrease in anti-Leishmania antibody levels in the peripheral blood11; 
that is, in only 40-50% of VL/HIV-AIDS cases, specific antibodies are 
detected1. Conversely, assessment of Leishmania antigen in urine by latex 
agglutination test showed a sensitivity of 85-100%1. Polymerase chain 
reaction (PCR) in peripheral blood and bone marrow is a useful tool to 
diagnose, for follow-up, and detect relapses22. Although the literature 
shows that serological analyses are not the most convenient in patients 
presenting co-infection1,6, two serological tests (direct agglutination 
test and rK39-based rapid immunochromatographic test) performed 
enabled the diagnosis of such cases in 2011 and 2012. In the same 
years, latex agglutination test and PCR test showed positive results, 
thus, confirming the data in the literature. Similar to the finding in our 
study, CAVALCANTI et al. (2012), described a series of case studies of 
co-infection in the main hospitals of Recife, Brazil10.
There is currently sufficient evidence suggesting that secondary 
prophylaxis provides some protective effect but does not completely 
prevent the occurrence of relapse11. A meta-analysis study described 
that the average incidence of relapse in patients who did not receive 
secondary prophylaxis was 67%, whereas in those who received it was 
31%16. Current recommendations from the Ministry of Health of Brazil2 
for the diagnosis, treatment, and follow-up of patients presenting co-
infection state that the “efficacy of the secondary prophylaxis after the 
first successfully treated VL infection, was not completely established.” 
The suggested secondary prophylaxis (Table 1) was poorly adopted, 
thus, compromising the clinical follow-up. Based on this case study 
and literature review, it is evident that co-infection presents typical 
clinical, diagnostic, and therapeutic features, and can be observed in 
the prognosis of the disease. Therefore, prospective studies are required 
to clarify gaps such as the efficacy of secondary prophylaxis and need 
for clinical and laboratory monitoring tools for the early assessment of 
relapse or re-infection.
RESUMO
Estudo de caso de paciente com múltiplos episódios da coinfecção 
HIV-AIDS e leishmaniose visceral
Relato de caso de paciente masculino de 45 anos, agricultor, residente 
na zona da mata do Estado de Pernambuco, diagnosticado com HIV em 
1999 e em uso de ARV. Em 2005 foi registrada a primeira ocorrência 
de LV através do diagnóstico parasitológico a partir do aspirado da 
medula óssea. À admissão no hospital apresentava-se com febre, 
hepatoesplenomegalia, perda de peso e diarréia. Desde então houve a 
ocorrência de mais sete episódios de LV, tendo ocorrido em media, um 
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evento a cada ano (2005-2012 exceto em 2008). O paciente apresentou, 
em 2011, um quadro cutâneo disseminado, sendo realizada biopsia 
de pele que evidenciou formas amastigotas de Leishmania no exame 
histopatológico. Em 2005, o tratamento foi realizado com antimoniato 
de N-metil-glucamina e anfotericina B desoxicolato, mas desde 2006, 
devido à toxicidade, o medicamento de escolha foi a anfotericina B 
lipossomal. Como recomendado pelo Ministério da Saúde, esse relato 
reforça a necessidade de que os casos de HIV residentes em área endêmica 
de LV deverão ter inserido em seu protocolo de acompanhamento essa 
parasitose, principalmente após o primeiro episódio.
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